Home Cancer Gene Mutations and Fusions RUNX1 Mutation Test: AML, Myelodysplastic Syndrome, Mutation Status, and Prognosis

RUNX1 Mutation Test: AML, Myelodysplastic Syndrome, Mutation Status, and Prognosis

By
Vita Library
-
2
Understand RUNX1 mutation testing in AML and MDS, including modern WHO/ICC classification, ELN risk, prognosis, somatic versus germline findings, VAF limits, MRD context, and follow-up.

A RUNX1 mutation test looks for changes in RUNX1, a transcription-factor gene that helps blood stem cells mature normally. Acquired RUNX1 mutations occur in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and related myeloid neoplasms, where they can contribute to diagnosis, genetic risk classification, and prognosis. The meaning has changed with modern disease classifications: “AML with mutated RUNX1” is no longer used in the same way as it was in the 2016 World Health Organization classification. The 2022 International Consensus Classification includes RUNX1 among myelodysplasia-related gene mutations, while the WHO fifth edition uses a different gene list for AML, myelodysplasia-related. European LeukemiaNet (ELN) genetic risk also considers RUNX1 in the wider myelodysplasia-related mutation group, with important exceptions for favorable-risk AML. A RUNX1 mutation is therefore never interpreted by itself. Blast percentage, cytogenetics, co-mutations, prior MDS or cytotoxic therapy, treatment intensity, and possible germline origin all influence what the result means.

  • A RUNX1 mutation in AML or MDS usually represents an acquired myeloid-driver abnormality, but some RUNX1 variants are inherited.
  • RUNX1 mutation status can contribute to adverse-risk classification, but favorable defining abnormalities may take precedence.
  • The old diagnostic label “AML with mutated RUNX1” was changed in the 2022 WHO/ICC classification era.
  • A variant allele fraction near 50% does not prove germline RUNX1; confirmation requires an appropriate non-hematopoietic sample.
  • RUNX1 is not a stand-alone measurable residual disease marker for most patients; MRD strategy usually depends on the complete leukemia profile.

Table of Contents

What RUNX1 Does

RUNX1 encodes the alpha subunit of core-binding factor, a transcriptional regulator that controls genes needed for normal blood-cell development. It partners with CBFB and is essential for hematopoiesis. Disrupting RUNX1 can impair differentiation, alter stem-cell behavior, and cooperate with other mutations to produce a myeloid malignancy.

RUNX1 can be abnormal in several ways. The gene may acquire missense, nonsense, frameshift, splice-site, or larger structural changes. RUNX1 is also involved in chromosomal rearrangements, most famously RUNX1::RUNX1T1 in core-binding-factor AML. That fusion is biologically and clinically different from a RUNX1 point mutation and is classified separately.

This distinction matters because the phrase “RUNX1 positive” is too vague. A report should specify whether it found a sequence mutation, deletion, copy-number change, or fusion. AML with RUNX1::RUNX1T1 is generally a favorable-risk genetically defined subtype when appropriate criteria are met, whereas many non-fusion RUNX1 mutations occur in biologically different myeloid disease.

RUNX1 sequence mutations often coexist with mutations in splicing factors, chromatin regulators, signaling genes, or other transcription factors. The co-mutation pattern is one reason a broad myeloid panel is usually more informative than testing RUNX1 alone.

When RUNX1 Testing Is Used

RUNX1 is commonly included in next-generation sequencing panels ordered for suspected or confirmed AML, MDS, MDS/AML overlap disorders, and other myeloid neoplasms. Testing may be performed on bone marrow aspirate, peripheral blood with sufficient circulating disease, or another validated specimen.

At diagnosis, molecular profiling helps answer several questions at once:

  • Does the leukemia meet criteria for a genetically defined AML category?
  • Are myelodysplasia-related mutations present?
  • Which ELN genetic risk group applies?
  • Are there targetable alterations such as FLT3 or IDH1/2?
  • Is there an established molecular marker suitable for follow-up?
  • Does the pattern raise concern for inherited predisposition?

RUNX1 should therefore be read in the context of cytogenetics and the rest of the mutation panel. For example, an NPM1 mutation, a core-binding-factor fusion, or another defining abnormality can change both classification and risk interpretation.

Testing may also be repeated at relapse because the leukemic clone can evolve. Some mutations disappear, others expand, and new resistance or progression-associated abnormalities emerge. However, repeat sequencing is most useful when it can change diagnosis, treatment selection, transplant planning, or trial eligibility.

In MDS, RUNX1 mutations contribute to molecular risk assessment and may be associated with higher risk of progression. Modern MDS prognostic systems increasingly incorporate mutation data alongside blood counts, marrow blasts, and cytogenetics.

RUNX1 in Modern AML Classification

The classification change is one of the most important points to understand about RUNX1 testing.

Under the 2016 WHO classification, “AML with mutated RUNX1” was a provisional entity. That label led many older reports and articles to treat any RUNX1-mutated AML as a distinct disease category.

The 2022 classification systems changed that framework. The International Consensus Classification (ICC) created a category of AML with myelodysplasia-related gene mutations and includes RUNX1 among the qualifying genes, assuming a higher-priority defining genetic lesion is not present and other criteria are met.

The WHO fifth edition also created AML, myelodysplasia-related, but its mutation-defined list differs from the ICC and does not use RUNX1 in exactly the same way. WHO and ICC therefore can assign the same patient differently in some edge cases. This is not a laboratory error; it reflects two accepted classification systems with different criteria.

ELN 2022 genetic risk classification also groups RUNX1 with myelodysplasia-related gene mutations in the adverse-risk category, but the rule is hierarchical. Adverse-risk mutation status should not automatically override a favorable-risk AML-defining abnormality. For example, a favorable core-binding-factor leukemia is not simply converted to adverse risk because a myelodysplasia-related mutation happens to be present.

This hierarchy prevents a common interpretation mistake: the gene name alone is not the diagnosis. The pathologist or hematologist integrates morphology, blast count, cytogenetics, fusion testing, and the entire mutation profile before assigning a final classification.

How to Interpret a RUNX1 Result

A typical NGS report lists the exact nucleotide and protein change, variant allele fraction (VAF), classification, and sometimes a clinical tier.

A pathogenic or likely pathogenic somatic RUNX1 mutation means the alteration is believed to disrupt RUNX1 function or contribute to myeloid neoplasia. The report should then be interpreted within the current classification and risk framework.

A variant of uncertain significance (VUS) should not be treated like a proven myeloid driver. VUS findings may be rare benign variants or changes without enough functional evidence. They usually should not determine AML risk group, transplant decisions, or family testing by themselves.

A negative result means no reportable RUNX1 alteration was detected within the assay’s scope. It does not rule out AML or MDS, and it does not mean the disease is favorable risk. Many other molecular and cytogenetic abnormalities can drive myeloid malignancy.

VAF can provide clues about clonal architecture but is not a direct measure of the percentage of leukemia cells. A heterozygous variant in a nearly pure leukemic sample may appear near 50%, while copy-number changes, normal-cell contamination, subclones, or loss of the normal allele can shift that value substantially.

The VAF also cannot reliably distinguish somatic from germline RUNX1. A mutation near 50% is one reason to consider inherited predisposition, but the same pattern is common in dominant leukemic clones.

RUNX1 and Prognosis

Across many cohorts, RUNX1-mutated AML has been associated with lower complete-remission rates and poorer survival compared with RUNX1-wild-type AML, but prognosis is not determined by RUNX1 alone. Age, fitness, cytogenetics, co-mutations, disease origin, therapy type, transplant eligibility, and response depth all matter.

A 2022 cohort study and meta-analysis found overall outcomes generally favored RUNX1-wild-type AML, while also showing that the prognostic effect varied in subgroups. This illustrates why a mutation should not be converted into an individualized survival estimate without context.

In MDS, RUNX1 mutations have been linked to shorter survival and increased risk of leukemic progression in several studies. They may appear at diagnosis or emerge during clonal evolution. Modern molecular scoring systems account for this broader genomic landscape rather than assigning risk from one gene.

Treatment decisions should similarly avoid one-gene shortcuts. RUNX1 currently is not a standard direct drug target in the way FLT3 or IDH1 can be. Patients may receive intensive chemotherapy, lower-intensity regimens, venetoclax-based therapy, allogeneic stem-cell transplantation, or investigational treatment depending on the full disease profile and clinical situation.

Response to treatment also changes prognosis. A patient with adverse baseline genetics who achieves a deep remission may have a different outlook from someone with persistent disease after induction. measurable residual disease testing is therefore often an important part of ongoing risk assessment.

RUNX1 itself may be trackable by sequencing in research or selected clinical workflows, but it is not always an ideal sole MRD marker. Some myeloid mutations can persist in preleukemic hematopoietic clones even when overt AML is in remission. MRD interpretation should use markers and assays validated for that disease.

Somatic Versus Germline RUNX1

Most RUNX1 mutations detected in adults with AML or MDS are acquired, but inherited RUNX1 pathogenic variants cause a recognized cancer-predisposition syndrome often called familial platelet disorder with associated myeloid malignancy.

People with germline RUNX1 variants may have lifelong mild-to-moderate thrombocytopenia, platelet-function abnormalities, easy bruising or bleeding, and an increased risk of MDS or leukemia. The family history can show low platelets, bleeding, leukemia, or unexplained early hematologic disease across generations—but the presentation is variable, and some carriers have near-normal blood counts.

Features that can prompt germline evaluation include a RUNX1 variant with a VAF compatible with heterozygosity, younger age at myeloid malignancy, a personal history of longstanding thrombocytopenia, or a suggestive family history. None proves inheritance.

Confirmatory testing requires special care in patients with hematologic cancers. Blood, bone marrow, and often saliva can contain the malignant or clonal hematopoietic cells, so they may reproduce the somatic mutation and falsely appear “germline.” Cultured skin fibroblasts are a commonly used source of non-hematopoietic DNA when definitive germline confirmation is necessary. Other tissues may be acceptable under genetics-laboratory protocols.

This distinction has practical consequences. A germline RUNX1 result can change family counseling and donor selection for stem-cell transplantation. A related donor who carries the same pathogenic variant may be unsuitable as a donor even if blood counts appear normal.

Testing Limitations and Next Steps

NGS panels differ in coverage and sensitivity. Most detect common single-nucleotide variants and small insertions/deletions well, but large exon deletions, complex structural changes, or low-level variants may require specialized analysis. Recent work has shown that somatic exonic RUNX1 deletions can occur in AML, so a panel that only reports small sequence changes may not capture every clinically relevant event.

Sample quality also matters. A low-blast marrow or peripheral blood specimen can dilute the clone below the assay’s detection limit. Conversely, a post-treatment sample may show persistent age-related or preleukemic clones that do not equal active leukemia.

A useful result review asks:

  1. Is this a RUNX1 sequence mutation or a RUNX1 fusion?
  2. Is the variant pathogenic/likely pathogenic or a VUS?
  3. Which classification system is the pathology report using—WHO fifth edition, ICC, or both?
  4. What other mutations, cytogenetic abnormalities, and AML-defining lesions are present?
  5. Does the result change ELN risk after applying the hierarchy correctly?
  6. Is there any reason to suspect a germline RUNX1 predisposition?
  7. What MRD method will be used after treatment?

A RUNX1 mutation is therefore best viewed as one part of an integrated myeloid diagnosis. Its clinical value comes from combining it with morphology, cytogenetics, co-mutations, treatment response, and inherited-risk assessment rather than treating it as a stand-alone prognosis label.

References

Disclaimer

RUNX1 results in AML or MDS require interpretation with the complete pathology, cytogenetic, and molecular profile, and classification criteria continue to evolve. Suspected germline RUNX1 variants need dedicated genetics evaluation using an appropriate non-hematopoietic sample. This article is educational and does not replace hematology or genetics care.

RELATED ARTICLESMORE FROM AUTHOR